ANI Pharmaceuticals (ANIP)

[Rolling inflaton]

Anabasum would be expected to bring in excess of $1bn/yr revenues only with scleroderma. This disease has 70k patients with high morbidity and no good treatment options, and results from clinical trials have been outstanding so far. Beyond this, the posibilities for an anti-inflammatory and anti-fibrotic drug with no side effects are huge. And apart from the clinical trials, the amount of science backing its effects and its mechanism of action is very impressive. With CRBP having 50M shares fully diluted, you can make the numbers...